Time-resolved fluorescence immunoassay
Time-resolved fluorescence immunoassay

Compared with standard luminescence-detection methods that use wavelength to differentiate target luminescence from background signal, Time Resolved Fluorescence Immunoassay (TRFIA) separates the luminescence of interest from the background signal by measuring the lifetime difference as well as wavelength difference. After excitation of a luminescent label with a short pulse of light, long-lived luminescence is measured only a short time after autofluorescence and light-scattering effects hace completely dissipated. Such time-resolved measurments can be repeated and combined to fine-tune signal-to-noise ratios and improve sensitivity. Overall, time-resolved luminescence measurements increase the sensitivity by two or more orders of magnitude relative to conventional luminescence measurements in liguid samples.

Along with its proprietary luminescence encapsulation technique for obtaining strong and long-lived luminescence labels, Lumigenex has been able to successfully leverage its time-resolved luminescence membrane assay technique, exclusively licensed from Kimberly-Clark Corporation, to commercialize numerous quantitative test kits.

April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.